Corporate Monitorships


Calibrate Your Compliance Training: A Practical Framework

Dan O’Connor

Senior Vice President, PharmaCertify, NXLevel Solutions

June 15th, 2021

2:00 PM – 3:00 PM EDT

Earn CLE credits*
(*pending final approval)

During this session we will provide both theoretical grounding and practical approaches for aligning your compliance training program with guidance from the Department of Justice as outlined in their publication Evaluation of Corporate Compliance Programs (June 2020). We will examine the obvious (e.g., training based on risk) as well less-obvious factors that should be considered when devising compliance training plans.

We will unleash a little bit of training geekiness on you and, more importantly, share case studies and practical examples to give you real-world guidance that you can apply immediately no matter the budget and internal capabilities at your company. Key takeaways will include:

  • The effects of the forgetting curve on compliance – and how to overcome these effects.
  • How to employ the Risk-Frequency Framework to make training decisions.
  • How to apply the Compliance Training Portfolio model to optimize your time and budget.
  • Practical ways to evaluate the effectiveness of your training.

Please join us for this dynamic and interactive session!

Earn CLE credits*
(*pending final approval)

SPEAKERS


Dan O’Connor

Senior Vice President, PharmaCertify, NXLevel Solutions


Dan heads PharmaCertify, the life science compliance training practice within NXLevel Solutions. Since 2004, PharmaCertify has focused exclusively on providing innovative commercial compliance training solutions to pharmaceutical and medical device companies. PharmaCertify is acknowledged as a thought leader and innovator in compliance training and Dan shares his practical expertise at 3-4 large industry conferences each year. Dan has over thirty years in the field of learning and development and has a Certificate in U.S. Healthcare Compliance from the Seton Hall University School of Law.